福安药业(300194) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥562,269,601.28, a decrease of 14.09% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥85,129,279.72, down 6.40% year-on-year, while net profit excluding non-recurring gains and losses was ¥79,621,103.07, a decrease of 2.68%[3]. - For the first nine months of 2024, the company achieved a revenue of ¥1,995,281,936.35, a slight increase of 0.62% year-on-year, and a net profit of ¥301,606,802.14, up 19.76%[6]. - Total operating revenue for Q3 2024 reached ¥1,995,281,936.35, a slight increase from ¥1,982,986,710.24 in the same period last year, reflecting a growth of approximately 0.15%[17]. - The total profit for the third quarter of 2024 is CNY 342,706,464.18, an increase from CNY 276,604,798.53 in the same period last year, representing a growth of approximately 23.8%[18]. - The net profit attributable to shareholders of the parent company is CNY 301,606,802.14, compared to CNY 251,841,424.68 in the previous year, marking an increase of about 19.7%[18]. - Basic and diluted earnings per share are both CNY 0.25, up from CNY 0.21 in the previous year, indicating an increase of about 19%[18]. Cash Flow - The company's cash flow from operating activities for the first nine months was ¥300,844,286.23, representing a significant increase of 79.23%[3]. - The net cash flow from operating activities increased to ¥300,844,286.23, a growth of 79.23% compared to the previous period's ¥167,853,721.28[8]. - The total cash inflow from operating activities is CNY 2,001,917,548.69, compared to CNY 1,950,261,682.11 in the previous year, showing a slight increase of about 2.7%[20]. - The operating cash flow for the period is CNY 300,844,286.23, significantly up from CNY 167,853,721.28 in the same quarter last year, indicating a growth of approximately 79.2%[20]. - The net cash flow from financing activities decreased significantly to -¥213,086,432.51, a decline of 246.79% compared to a net increase of ¥145,167,086.20 in the same period last year[8]. - The net cash flow from financing activities is -CNY 213,086,432.51, a decrease from CNY 145,167,086.20 in the previous year, indicating a decline of about 246.5%[21]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥6,040,326,243.55, reflecting a 1.08% increase from the end of the previous year[3]. - Total assets increased to ¥6,040,326,243.55 from ¥5,975,931,145.19, representing a growth of approximately 1.1%[16]. - The company's equity attributable to shareholders increased by 6.15% to ¥4,399,795,444.53 compared to the end of the previous year[3]. - The company's equity attributable to shareholders increased to ¥4,399,795,444.53 from ¥4,144,805,149.99, indicating a growth of about 6.2%[15]. - Current liabilities rose to ¥1,309,414,118.79 from ¥1,195,046,283.58, an increase of about 9.5%[15]. - Total liabilities decreased to ¥1,636,299,673.58 from ¥1,827,207,131.34, reflecting a reduction of approximately 10.5%[15]. Investments and Expenses - The company reported a significant increase of 493.65% in trading financial assets, totaling ¥30,000,520.55, due to increased investment in financial products[6]. - The company's financial expenses decreased by 90.23% to -¥4,956,140.39, primarily due to reduced bank loans and corresponding interest expenses[7]. - The company experienced a 278.72% increase in credit impairment losses, amounting to ¥4,992,614.01, as a result of reduced bad debt provisions[7]. - Research and development expenses for the quarter were ¥95,368,357.23, slightly down from ¥98,871,009.50, a decrease of about 2.5%[17]. - The cash outflow from investing activities is CNY 267,993,074.35, up from CNY 195,179,390.49 in the same period last year, reflecting an increase of approximately 37.2%[21]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 40,158, with the top ten shareholders holding significant stakes[9]. - Wang Tianxiang, the largest shareholder, holds 24.00% of the shares, amounting to 285,499,420 shares[9]. - The total number of restricted shares held by major shareholders remains significant, with Wang Tianxiang holding 214,124,565 restricted shares[11]. Inventory and Receivables - Inventory increased to ¥783,360,898.85 from ¥707,801,281.40, indicating a rise in stock levels[13]. - Accounts receivable decreased to ¥233,222,961.61 from ¥250,701,696.09, reflecting improved collection efforts[13]. Future Outlook - The company plans to maintain a strategy focused on market expansion and new product development in the upcoming quarters[10].